In this review:
Abiraterone acetate + prednisone with ADT
Abiraterone in newly diagnosed patients receiving ADT
Galeterone vs enzalutamide in AR-V7+ patients
Continued enzalutamide after PSA progression in mCRPC
Cross-over study of abiraterone vs enzalutamide for mCRPC
Abiraterone plus veliparib for mCRPC
Duration of ADT in high-risk prostate cancer
Extended vs limited pelvic lymphadenectomy
Stereotactic ablative radiation therapy for OPC
Please login below to download this issue (PDF)